GSK Does Not Expect Overly Restrictive Formularies Under Part D
This article was originally published in The Pink Sheet Daily
Executive Summary
GlaxoSmithKline does not expect formularies under the Medicare Part D drug benefit program to be overly restrictive
You may also be interested in...
Medco, GSK Reach Formulary Agreement For Medicare Part D
Medco describes the agreement as an "innovative collaboration" in a press release. Under the deal, Medco and GSK will share responsibility for providing access to and ensuring appropriate use of the products, the PBM said.
Able Unable To Reform On Its Own? Firm Seeks Consent Decree To Address Manufacturing Issues
“We are prepared to enter discussions toward a decree at FDA’s earliest convenience,” Able says in letter to FDA. Company is pursuing consent decree instead of responding to FDA Form 483 report citing manufacturing deficiencies. The letter follows CEO Maury’s resignation the previous day.
Astellas Ends Aczone Acne Treatment Collaboration Agreement With QLT
QLT now has worldwide marketing rights to the topical acne treatment. Astellas believes labeling proposed by FDA will limit the market profile for Aczone, the company said. Aczone’s user fee deadline is July 7.